Literature DB >> 16970995

Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study.

Emilie Frobert1, Tadamasa Ooka, Jean-Claude Cortay, Bruno Lina, Danielle Thouvenot, Florence Morfin.   

Abstract

By site-directed mutagenesis, we investigate the role of six mutations of herpes simplex virus type 1 thymidine kinase (TK) gene in the acquisition of resistance to acyclovir (ACV). TK activity was not impaired by substitutions located at codons 17, 161 and 374 and these mutations were thus related to TK gene polymorphism. Mutations His105Pro, Leu364Pro and Asp162Ala lead to the loss of TK activity that could result in ACV-resistance.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16970995     DOI： 10.1016/j.antiviral.2006.08.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  6 in total

1.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Antiviral activity of recombinant cyanovirin-N against HSV-1.

Authors:  Hong Yu; Zong-tao Liu; Rui Lv; Wen-qing Zhang
Journal:  Virol Sin       Date:  2010-12-21       Impact factor: 4.327

3.  Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Authors:  Susanne Schmidt; Kathrin Bohn-Wippert; Peter Schlattmann; Roland Zell; Andreas Sauerbrei
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.

Authors:  Thibaut Deschamps; Hope Waisner; Christos Dogrammatzis; Anuradha Roy; Shibin Chacko; Chamani Perera; Thomas E Prisinzano; Maria Kalamvoki
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 5.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

6.  An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Authors:  Paul J Park; Thessicar E Antoine; Asim V Farooq; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.